Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway

Journal of Pathology

Volumn 238, Issue 3, 2016, Pages 470-482

  Chiu, Chen Yuan ^a   Yang, Rong Sen ^a   Sheu, Meei Ling ^b   Chan, Ding Cheng ^a   Yang, Ting Hua ^c   Tsai, Keh Sung ^a   Chiang, Chih Kang ^a,d   Liu, Shing Hwa ^a,c,e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

advanced glycation end products; alagebrium chloride; diabetic myopathy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ATROGIN 1; GLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE B; FBXO32 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; MUSCLE PROTEIN; THIAZOLE DERIVATIVE; TUMOR ANTIGEN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ENDURANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE EXERCISE; MUSCLE FATIGUE; MUSCLE MASS; MUSCLE REGENERATION; MUSCLE WEAKNESS; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SKELETAL MUSCLE ATROPHY; SOLEUS MUSCLE; VERY ELDERLY; ANIMAL; ATROPHY; CASE CONTROL STUDY; DIABETES MELLITUS, EXPERIMENTAL; METABOLISM; MUSCULAR DISEASES; PATHOLOGY; PHYSIOLOGY; REGENERATION; SKELETAL MUSCLE CELL;

AGED; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, NEOPLASM; ATROPHY; CASE-CONTROL STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE FATIGUE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; REGENERATION; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; THIAZOLES;

EID: 84956585988     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4674     Document Type: Article

References (47)

1. Atkins RC, Zimmet P,. Diabetic kidney disease: act now or pay later. Nephrol Dial Transpl 2010; 25: 331-333.
2. Zhao J, Randive R, Stewart JA,. Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. World J Diabetes 2014; 5: 860-867.
3. Hahl J, Hämäläinen H, Sintonen H, et al., Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications. Qual Life Res 2002; 11: 427-436.
4. Foos V, Varol N, Curtis BH, et al., Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ 2015; 18: 420-432.
5. Krause MP, Riddell MC, Hawke TJ,. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes 2011; 12: 345-364.
6. Grøntved A, Pan A, Mekary RA, et al., Muscle-strengthening and conditioning activities and risk of type 2 diabetes: a prospective study in two cohorts of US women. PLoS Med 2014; 11: e1001587.
7. Tanji N, Markowitz GS, Fu C, et al., Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
8. Jiang J, Chen P, Chen J, et al., Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis. Atherosclerosis 2012; 224: 187-194.
9. Zhang MH, Feng L, Zhu MM, et al., The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and high-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol 2014; 151: 591-600.
10. Hanssen NM, Beulens JW, van Dieren S, et al., Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015; 64: 257-265.
11. Haus JM, Carrithers JA, Trappe SW, et al., Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol (1985) 2007; 103: 2068-2076.
12. Momma H, Niu K, Kobayashi Y, et al., Skin advanced glycation end product accumulation and muscle strength among adult men. Eur J Appl Physiol 2011; 111: 1545-52.
13. Snow LM, Fugere NA, Thompson LV,. Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci 2007; 62: 1204-1210.
14. Snow LM, Thompson LV,. Influence of insulin and muscle fiber type in n-ε-(carboxymethyl)-lysine accumulation in soleus muscle of rats with streptozotocin-induced diabetes mellitus. Pathobiology 2009; 76: 227-234.
15. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al., Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4634.
16. Little WC, Zile MR, Kitzman DW, et al., The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195.
17. Willemsen S, Hartog JW, Hummel YM, et al., Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial. Eur J Heart Fail 2010; 12: 294-300.
18. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC, 1996.
19. -/- mice. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1347-1355.
20. Kawai H, Nishino H, Kusaka K, et al., Experimental glycerol myopathy: a histological study. Acta Neuropathol 1990; 80: 192-197.
21. Chiu CY, Yen YP, Tsai KS, et al., Low-dose benzo(a)pyrene and its epoxide metabolite inhibit myogenic differentiation in human skeletal muscle-derived progenitor cells. Toxicol Sci 2014; 138: 344-353.
22. Lavasani M, Lu A, Thompson SD, et al., Isolation of muscle-derived stem/progenitor cells based on adhesion characteristics to collagen-coated surfaces. Methods Mol Biol 2013; 976: 53-65.
23. Asakura A1, Seale P, Girgis-Gabardo A, et al., Myogenic specification of side population cells in skeletal muscle. J Cell Biol 2002; 159: 123-134.
24. Chen YJ, Sheu ML, Tsai KS, et al., Advanced glycation end products induce peroxisome proliferator-activated receptor-γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS One 2013; 8: e66611.
25. Fry AC,. The role of resistance exercise intensity on muscle fibre adaptations. Sports Med 2004; 34: 663-679.
26. Hu Z, Wang H, Lee IH, et al., PTEN inhibition improves muscle regeneration in mice fed a high-fat diet. Diabetes 2010; 59: 1312-1320.
27. Lokireddy S, Mouly V, Butler-Browne G, et al., Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. Am J Physiol Cell Physiol 2011; 301: C1316-1324.
28. 2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific ring finger protein 1 (MuRF1). J Biol Chem 2015; 290: 9183-9194.
29. Chargé SB, Rudnicki MA,. Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004; 84: 209-238.
30. Mouisel E, Vignaud A, Hourdé C, et al., Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24 month-old) dystrophic mdx mice. Muscle Nerve 2010; 41: 809-818.
31. Kim TN, Park MS, Yang SJ, et al., Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010; 33: 1497-1499.
32. Leenders M, Verdijk LB, van der Hoeven L, et al., Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 2013; 14: 585-592.
33. Yan SF, Ramasamy R, Naka Y, et al., Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169.
34. Riuzzi F, Sorci G, Sagheddu R, et al., HMGB1-RAGE regulates muscle satellite cell homeostasis through p38-MAPK- and myogenin-dependent repression of Pax7 transcription. J Cell Sci 2012; 125: 1440-1454.
35. Beccafico S, Riuzzi F, Puglielli C, et al., Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. Age (Dordr) 2011; 33: 523-541.
36. Yu W, Wu J, Cai F, et al., Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 2012; 7: e52013.
37. Verdijk LB, Dirks ML, Snijders T, et al., Reduced satellite cell numbers with spinal cord injury and aging in humans. Med Sci Sports Exerc 2012; 44: 2322-2330.
38. Lara-Pezzi E, Winn N, Paul A, et al., A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J Cell Biol 2007; 179: 1205-1218.
39. Pansters NA, Schols AM, Verhees KJ, et al., Muscle-specific GSK-3β ablation accelerates regeneration of disuse-atrophied skeletal muscle. Biochim Biophys Acta 2015; 1852: 490-506.
40. Williamson DL, Butler DC, Alway SE,. AMPK inhibits myoblast differentiation through a PGC-1α-dependent mechanism. Am J Physiol Endocrinol Metab 2009; 297: E304-314.
41. Yang SY, Hoy M, Fuller B, et al., Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways. Lab Invest 2010; 90: 391-401.
42. Vaitkevicius PV, Lane M, Spurgeon H, et al., A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98: 1171-1175.
43. Liu J, Masurekar MR, Vatner DE, et al., Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003; 285: H2587-2591.
44. Lassila M, Seah KK, Allen TJ, et al., Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-2138.
45. Tan AL, Sourris KC, Harcourt BE, et al., Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010; 298: F763-770.
46. Thallas-Bonke V, Coughlan MT, Tan AL, et al., Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology (Carlton) 2013; 18: 47-56.
47. Wang L, Tian W, Uwais Z, et al., AGE-breaker ALT-711 plus insulin could restore erectile function in streptozotocin-induced type 1 diabetic rats. J Sex Med 2014; 11: 1452-1462.